Socially Isolated Older Adults Living With Dementia
3. januar 2022 oppdatert av: Hyun-Jun Kim, University of Washington
The lack of efficacious research-based interventions for sexual and gender minority (SGM) older adults living with Alzheimer's disease and other dementias, combined with the heightened risk of cognitive impairment in this population, presents a significant public health problem.
SGM older adults are at elevated risk of social isolation and experience significant barriers to healthcare access.
Existing interventions for older adults with dementia have been found to be effective for caregiving dyads.
Yet SGM older adults, compared to heterosexuals, are significantly less likely to be married or to have biological family members to support them.
A significant proportion of SGM older adults living with dementia have no caregiver or care network.
The goal of the proposed research is to design and pilot test the cultural appropriateness, acceptability, and feasibility of an innovative translation of a personalized care network-RDAD (Reducing Disability in Alzheimer's Disease) to support those living with dementia without a family caregiver, directly addressing unique SGM-specific risk factors.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
We will address the following aims:
Aim 1. Develop a personalized care network-RDAD intervention suitable for SGM older adults living with dementia without caregivers.
Aim 2. Implement a preliminary randomized controlled trial (RCT) of 30 participants with 2 arms (routine medical care vs. the personalized care network-RDAD approach) to assess the acceptability, feasibility, and initial efficacy of the intervention.
Studietype
Intervensjonell
Registrering (Faktiske)
30
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- UWashington
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
50 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Age at enrollment is 50 years of age or older
- Self-identify as LGBT (or sexual or gender non-binary or same sex sexual behavior)
- Have early stage dementia, including Alzheimer's disease or needs help with complex daily activities
- Living in the community, not in a care facility.
Exclusion Criteria:
- Known terminal illness (with death anticipated within the next 12 months)
- Hospitalization for a psychiatric disorder in the 12 months prior to baseline
- Have more than early stage dementia
- Any physical limitations/chronic conditions preventing participation in an exercise program.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Personalized care network
9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
|
The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
|
|
Ingen inngripen: Routine medical care
No intervention
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Physical Activity
Tidsramme: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Minutes spent on exercising per week in the past month were calculated from the following two questions: (1) How much time did you spend on exercises (hours per day) on a typical day during the last month; (2) How many days did you spend on exercises during the last month.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
|
Change in Physical Functioning
Tidsramme: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Physical Functioning subscale of the Medical Outcomes Study 36-Item Short Form (SF-36) consists of 10 items and measures how much participants' health status limits their activities including walking, climbing, lifting, and bathing or dressing oneself, based on self-reports.
Each item is measured a 3-point scale (1 = Yes, limited a lot; 2 = Yes, limited a little; 3 = No, not limited at all), then recoded into 0, 50, and 100, respectively.
The recoded scores are averaged to generate a summary score with its possible range from 0 to 100.
Higher scores indicate better physical functioning.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Quality of Life
Tidsramme: Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Quality of Life in Alzheimer's Disease (QOL-AD) is a 13-item scale that measures participant's self-reported feelings about different aspects of life including energy, mood, living situation, memory, family, friends, ability, and money.
Each item has a 4-point response scale (1 = poor; 2 = fair; 3 = good; 4 = excellent).
The summary score is a sum of the 13 items with its possible range from 13 to 52.
Higher scores indicate higher quality of life.
|
Baseline (pre-treatment) and 7 weeks (post-treatment)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Hyun-Jun Kim, PhD, University of Washington
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. august 2020
Primær fullføring (Faktiske)
30. desember 2020
Studiet fullført (Faktiske)
30. desember 2020
Datoer for studieregistrering
Først innsendt
7. september 2018
Først innsendt som oppfylte QC-kriteriene
7. september 2018
Først lagt ut (Faktiske)
12. september 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. februar 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
3. januar 2022
Sist bekreftet
1. januar 2022
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00005149
- 5P30AG034592-05 (U.S. NIH-stipend/kontrakt)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .